Clinical trial
Phase IIb Clinical Trial With TGF-β2 Antisense Compound AP 12009 for Recurrent…
NCT00431561 · Isarna Therapeutics GmbH, Industry · Completed
Key facts
| NCT number | NCT00431561 |
|---|---|
| Title | Phase IIb Clinical Trial With TGF-β2 Antisense Compound AP 12009 for Recurrent or Refractory High-grade Glioma |
| Official title | Multi-national, Open-label, Active-controlled, Randomized Dose-finding Study to Evaluate Efficacy of 2 Doses of AP 12009 in Recurrent Glioma, Administered Intratumorally as Continuous High-flow Microperfusion Over 7 Days Every Other Week |
| Lead sponsor | Isarna Therapeutics GmbH, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Glioblastoma, Anaplastic Astrocytoma |
| Intervention type | Device, Drug, Procedure |
| Interventions | AP 12009 10 µM, AP 12009 80 µM, temozolomide or PCV, Drug delivery system for administration of AP 12009, Placement of Drug Delivery System |
| Enrollment | 141 |
| Start date | Apr 1, 2003 |
| Primary completion | Mar 1, 2009 |
| Completion | Mar 1, 2009 |
| First posted | Feb 6, 2007 |
| Last update posted | Dec 3, 2013 |
| Countries | Austria, Georgia, Germany, India, Israel, Russia |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: